

In Advanced Prostate Cancer... Symptoms Help Guide Your Clinical Approach¹



THERE ARE MULTIPLE WAYS TO MONITOR PROGRESSION OF BONE METASTATIC DISEASE

MONITORING MODALITIES	CLINICAL CONSIDERATIONS
 PSA Testing	<ul style="list-style-type: none">• Shown to be a predictor of disease progression and survival²• Should be used with other disease progression indicators³
 Radiographic Imaging	<ul style="list-style-type: none">• Utilized to diagnose metastasis and to identify disease progression^{4,5}• Modalities can range in specificity and sensitivity^{4,5}
 Symptoms Assessment	<ul style="list-style-type: none">• Multiple symptoms are associated with bone metastasis⁶• Patients often underreport their symptoms⁶

- Include clinical symptoms when monitoring disease progression

PATIENTS WITH BONE METASTATIC DISEASE EXHIBIT A RANGE OF SYMPTOMS BEYOND PAIN

- Fatigue, generalized weakness⁷
- Interference with daily activities⁸

- Impaired mobility⁷
- Pain and discomfort^{7,8}
- Interference with sleep⁸
- Loss of appetite⁹

- Neurologic impairment¹⁰
- Loss of bladder and bowel function⁷
- Pathological fracture¹¹
- Cord compression⁷

Early metastatic disease



Late metastatic disease

68% of patients ignore their symptoms; proactive discussion with your patients helps you evaluate progression of disease to determine therapeutic intervention⁶

In Advanced Prostate Cancer... Symptoms Help Guide Your Clinical Approach¹




HOW DO YOU IDENTIFY PATIENTS WITH ADVANCING mCRPC?



John M.

Recently John has been cutting back on activities he enjoys, like going on outings with his family.


"I love my grandchildren, but I just don't have the energy to keep up with them like I used to."



Mike R.

In the last couple of weeks, Mike has been having difficulty climbing the stairs to his bedroom.

"It just hurts when I lift my legs up."



Bill H.

Bill has lost 5 pounds since his last visit and his appetite is diminished.

"I feel fine but I really haven't been hungry."

Monitoring symptomatic progression is an important factor when considering your clinical approach in patients with advanced prostate cancer

mCRPC, metastatic castration-resistant prostate cancer; PSA, prostate-specific antigen.

References: 1. Cotter K, Konety B, Ordonez MA. Contemporary management of prostate cancer. *F1000Res*. 2016;5:1-8. 2. Koo KC, Park SU, Kim KH, et al. Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels. *Prostate Int*. 2015;3(1):10-15. 3. Bryce AH, Alumkal JJ, Armstrong A, et al. A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study. *Ann Oncol*. 2016;27 (suppl 6):vi261. 4. Garcia JR, Moreno C, Valls E, et al. Diagnostic performance of bone scintigraphy and (11) C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer. *Rev Esp Med Nucl Imagen Mol*. 2015;34(3):155-161. 5. Beheshti M, Vali R, Waldenberger P, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. *Eur J Nucl Med Mol Imaging*. 2008;35(10):1766-1774. 6. Bayer. MenWhoSpeakUp. Prostate Cancer Symptoms Survey: US Results, 2015. <http://www.menwhospeakup.com/index.php>. Accessed July 2015. 7. Farrell C. Bone metastases: assessment, management and treatment options. *Br J Nurs*. 2013;22(10):S4-S11. 8. Autio KA, Bennett AV, Jia X, et al. Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. *J Oncol Pract*. 2013;9(5):223-229. 9. Hamilton W, Barrett J, Stapley S, et al. Clinical features of metastatic cancer in primary care: a case-control study using medical records. *Br J Gen Pract*. 2015;65(637):e516-522. 10. Selvaggi G, Scagliotti GV. Management of bone metastases in cancer: a review. *Crit Rev Oncol Hematol*. 2005;56(3):365-378. 11. Jayasekera J, Onukwughu E, Bikov K, et al. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. *Pharmacoeconomics*. 2014;32(2):173-191.